ARA-290
ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR) without stimulating red-blood-cell production. Widely used in preclinical models of neuroinflammation, organ protection, and metabolic regulation, ARA-290 offers precise IRR engagement and robust cytoprotective signaling. Each 16 mg vial is manufactured under ISO-certified conditions, verified at ≥99% purity by HPLC, screened for endotoxin (<0.1 EU/mg), and delivered with a full Certificate of Analysis.
⚠️ Important Disclaimer
For Research Use Only. Not for human consumption or therapeutic treatment.
ARA-290
KEY HIGHLIGHTS
IRR-Mediated Neuroprotection
In rodent models of neural injury, ARA-290 reduces microglial activation and preserves neuronal viability via innate repair receptor signaling.
Tissue-Protective Signaling
ARA-290 activates anti-apoptotic pathways (e.g., Akt phosphorylation) in ischemia–reperfusion assays, limiting cell death in heart, kidney, and liver explants.
Anti-Inflammatory Modulation
Preclinical studies show ARA-290 lowers pro-inflammatory cytokines (TNF-α, IL-6) in macrophage and endothelial cultures, modeling resolution of acute inflammation.
Metabolic Regulation Insights
ARA-290 enhances insulin-sensitivity markers in adipocyte and hepatocyte assays, offering a tool for dissecting IRR-driven metabolic pathways.
Wound Healing Acceleration
In ex vivo skin models, ARA-290 promotes keratinocyte migration and matrix remodeling—accelerating wound-closure kinetics by up to 40%.
Lab-Grade Handling & Stability
Reconstitute ARA-290 in Sterile Water for Injection (SWFI) or Bacteriostatic Water (BAC). Store lyophilized at –20 °C; keep reconstituted peptide at 2–8 °C and use within 7 days for >98% integrity.
What Is ARA-290?
ARA-290, also known as Cibinetide, is a lab-engineered 11-amino-acid peptide fragment of erythropoietin that selectively engages the innate repair receptor (IRR). Unlike full-length EPO, ARA-290 triggers cytoprotective and anti-inflammatory pathways without stimulating erythropoiesis. In preclinical research, it’s applied to neural, cardiovascular, renal, and metabolic models to explore mechanisms of tissue protection, inflammation modulation, and cell-survival signaling.
Why Choose ARA-290?
Researchers choose ARA-290 for its unmatched selectivity: it binds the IRR to activate PI3K/Akt and STAT3 pathways that promote cell survival, reduce inflammatory damage, and enhance tissue repair. Its small size ensures rapid tissue penetration and consistent receptor engagement. Each vial is produced under ISO-certified, cGMP-like standards and validated by HPLC (>99% purity), MS/MS sequence confirmation, and endotoxin testing—guaranteeing reproducible results across neural, cardiac, and metabolic study designs.
What Sets ARA-290 Apart?
Unlike broader cytokine-mimetic peptides, ARA-290 isolates the reparative arm of EPO signaling via the IRR, avoiding any hematopoietic side effects. This targeted action enables clear investigation of cytoprotection in models of ischemia, neurodegeneration, and metabolic stress. Coupled with its demonstrated stability in both lyophilized and reconstituted forms, ARA-290 stands out as a precision tool for dissecting IRR-mediated tissue-repair and anti-inflammatory mechanisms.
Research Studies
Li et al. (2024), Int. J. Mol. Sci., 25(7):3854
This March 2024 paper demonstrates that ARA-290 treatment improves insulin signaling and reduces inflammatory markers in hepatocyte cultures exposed to high-glucose conditions, suggesting potential for metabolic-dysfunction research.
Zhang et al. (2024), CNS Neurosci Ther., 30(3):e14676
Published March 2024, this study shows ARA-290 crosses the blood–brain barrier in rodent models and attenuates microglial activation in an LPS-induced neuroinflammation assay, providing a new tool for CNS inflammatory research.
Wang et al. (2024), “The Role of Macrophage Efferocytosis in Apical Periodontitis,” Sci. Rep.
In April 2024, researchers reported that ARA-290 enhances macrophage efferocytosis (clearance of apoptotic cells) and reduces bone-resorptive cytokines in an ex vivo periapical lesion model, opening avenues for dental-inflammation studies.
ARA-290 FAQs
What is ARA-290 (Cibinetide) peptide?
ARA-290 is an 11-amino-acid EPO fragment that activates the innate repair receptor for tissue-protective signaling in research models.
How does ARA-290 reduce inflammation?
By engaging the IRR, ARA-290 downregulates TNF-α and IL-6 in macrophage and endothelial assays, modeling inflammation resolution.
What research applications use ARA-290?
Neural-injury, cardiac-ischemia, renal-protection, wound-healing, and metabolic-regulation studies frequently employ ARA-290.
How is ARA-290 reconstituted?
Reconstitute in Sterile Water for Injection (SWFI) or Bacteriostatic Water (BAC) per lab SOPs, then use within 7 days at 2–8 °C.
What is the recommended storage for ARA-290?
Store lyophilized at –20 °C. Reconstituted solutions remain stable at 2–8 °C for up to 7 days with >98% peptide integrity.
Does ARA-290 stimulate red-blood-cell production?
No. ARA-290 selectively activates the IRR and does not engage erythropoietic pathways.
What concentrations are typical for ARA-290 studies?
In vitro assays often use 100 nM–10 µM, while in vivo rodent studies use 0.1–1 mg/kg depending on the model.
Can ARA-290 be combined with other peptides?
Yes. It’s frequently co-studied with anti-inflammatory or metabolic peptides like BPC-157 or AOD-9604.
Is ARA-290 approved for human use?
No. ARA-290 is strictly for research use only and is not approved for therapeutic or veterinary applications.
Where is ARA-290 manufactured?
ARA-290 is synthesized in ISO-certified U.S. labs, validated by HPLC, MS/MS, and endotoxin screening for consistent research performance.